17 Nov 2016 10:13
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 October 2016
Net Assets | £217m |
Net Assets per share | 577p |
Share price | 535p |
Total value of unquoted investments | £31m |
Total number of portfolio companies | 77 |
Top Ten Holdings
Company Name | % NAV |
Celgene | 7.0 |
Biogen | 6.7 |
Incyte | 6.6 |
Regeneron | 5.7 |
Gilead | 4.9 |
Tesaro | 4.3 |
Genmab | 4.3 |
Alexion | 4.0 |
Actelion | 3.4 |
Entellus | 3.1 |
----------- | |
Total | 50.0 |
Geographical Allocation | % NAV |
US & Canada | 80 |
Europe & UK | 20 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 86 |
Unquoted | 14 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 52 |
Mid Cap =USD1-10BN | 24 |
Small Cap | 24 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 36 |
Orphan | 16 |
Inflammation | 10 |
Ophthalmology | 7 |
CNS | 6 |
Medtech | 4 |
Other | 21 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
17 NOVEMBER 2016
Int.biotech. (IBT)